Upadacitinib Hemihydrate
2 Inquiries
2050057-56-0
Shanghai Port
1kg/10kg
2023-08-03
Upadacitinib Hemihydrate,(S)-(+)-1-Boc-3-hydroxypyrrolidine
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceUpadacitinib is a selective and reversible Janus kinase (JAK) inhibitor recently approved by the European Medicine Agency and the Food and Drug Administration for the treatment of rheumatoid arthritis (RA).Basic Info
-
Product Name:
Upadacitinib hemihydrate
Other Name:1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, hydrate (2:1), (3S,4R)-;Upadacitinib hemihydrate;Upadacitinib Hydrate;Cinchonanium, 1-[13,5-bis(trifluoromethyllphenyllmethyl]-9-hydroxy-1'- [[3-(trifluoromethyl)phenyllmethyl},bromide(1:2), (8a,9R)-";ABT 494 hemihydrate;ABT494 hemihydrate;ABT-494 hemihydrate;(3S,4R)-3-ethyl-4-(3H-imidazolo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate
CAS No.:2050057-56-0
Molecular Formula:C17H21F3N6O2
InChIKeys:VJSRYIXHEWRBKD-NFGOAHBONA-N
Molecular Weight:398.39
Exact Mass:778.32505216
UNII:NEW4DV02U5
Categories:
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Upadacitinib Hemihydrate,(S)-(+)-1-Boc-3-hydroxypyrrolidine
-
Location:
Honggutan District, Nanchang City, Jiangxi Province
-
Payment Terms:
TT against copy of documents,L/C
-
Average lead Time:
50
-
Total Annual Revenue:
$2.5 million-$5 million
-
Total Employees:
11-50
-
Year of Establishment:
2021
-
-
Inquiry History2 Inquiries
Country Product Purchase Quantity Date Posted 
Pakistan
UPADACITINIB HEMIHYDRATE
225 G May 6, 2026 
South Korea
Upadacitinib Hemihydrate
100 G Mar 27, 2025 Post an enquiry for this product